Skip to content

Neuromuscular Characterisation in Late Adolescent and Adult Cystinosis Patients

Characterization of Neuromuscular Involvement in Late Adolescent and Adult Cystinosis Patients

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05545774
Acronym
Cystinose
Enrollment
20
Registered
2022-09-19
Start date
2022-09-22
Completion date
2025-09-11
Last updated
2025-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cystinosis

Keywords

cystinosis, neuromuscular disorder, respiratory function, swallowing disorder

Brief summary

The primary objective of the study is to evaluate the change in motor function of patients with cystinosis. The secondary objectives of the study: * assessment of the respiratory function; * assessment of the muscle function; * assessment of swallowing disorders; * assessment radiologically of the muscular efficiency; * assessment of lean mass / fat mass ratio; * assessment of sleeping disorders; * annual assessment of evolution of above functions. All patients will be examined by experienced neuromuscular specialist (Pr Pascal Laforêt) and pulmonologist specialized in neuromuscular disorders (Pr Hélène Prigent). All evaluations will be performed in Raymond-Poincaré hospital (Teaching hospital of Assistance Publique - Hopitaux de Paris (APHP) and University of Paris-Saclay) neuromuscular center, coordinated by Pr Pascal Laforêt.

Detailed description

This is a monocentric study. The enrollment will be performed as routine care in the department of neurology - neuromuscular center of Raymond Poincaré hospital (APHP). Patients with cystinosis will be consecutively invited to participate in the study until 20 patients are included. This will avoid selection bias if any. For eligible non included patients, a specific non-identifying registry will be set-up with a very restricted number of variables indicative of disease severity at baseline, allowing for a comparison of included and non-included patients. Participating cystinosis patients will be proposed to attend a one-day hospitalization. Evaluations will be performed during stable state upon baseline and during a follow-up visit 12 months later. The study expected duration is 30 months with 18 months for patients' inclusion and 12 month-follow-up.

Interventions

None listed

Sponsors

Cystinosis Research Foundation
CollaboratorOTHER
Assistance Publique - Hôpitaux de Paris
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
16 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients aged ≥ 16 years; * Genetically confirmed diagnosis of cystinosis; * Presenting motor deficiency of at least one muscle; * Covered by health insurance.

Exclusion criteria

* Patient refusal; * Foreign patients under AME health schema; * Patients under legal protection; * Pregnancy or breast-feeding.

Design outcomes

Primary

MeasureTime frameDescription
Change in motor function12 monthsBy the Motor Function Measure (MFM) quantitative scale to measure the functional capacities of motors (0-100%, higher scores mean better capacities).

Secondary

MeasureTime frameDescription
Change in walking capacity12 monthsby the 6-minutes walking test. Higher scores mean better outcome.
Change in the time to stand test12 monthsby the time to stand test. Higher scores mean better outcome.
Change in the the Box and block test12 monthsby the Box and block test. Higher scores mean better outcome.
Change in the Nine hole peg test12 monthsby the Nine hole peg test. Higher scores mean better outcome.
Change in Perdue pegboard test12 monthsby Perdue pegboard test. Higher scores mean better outcome.
Change in Kapanji test12 monthsby Kapanji test. Higher scores mean better outcome.
Change in pinch strength12 monthsby myopinch test. Higher value mean better outcome.
Change in grip strength12 monthsby myogrip test. Higher value mean better outcome.
Change in motor strength12 monthsBy Manual Muscle Testing (MMT). Higher scores mean better outcome.
Change in inspiratory muscles function12 monthsBy inspiratory maximal pressure. Higher value mean better outcome.
Change in expiratory muscles function12 monthsBy expiratory maximal pressure. Higher value mean better outcome.
Change in diaphragmatic performance12 monthsBy transdiaphragmatic pressures measurements. Higher value mean better outcome.
Incidence of breathing disorders during sleep12 monthsDetection by a polysomnography associated to capnography.
Change in ratio of fat mass/lean mass12 monthsBy osteodensitometry
Change in swallowing function - Sidney Swallow questionnaire12 monthsBy the Sidney Swallow questionnaire. Higher scores mean better outcome.
Change in swallowing function - Salassa and McHorney scores12 monthsBy the Salassa and McHorney scores. Higher scores mean better outcome.
Change in swallowing function - time of swallowing12 monthsBy the time of swallowing 80 ml of water (normal = 3-4 sec). Higher values mean worse outcome.
Change in vital capacity12 monthsBy spirometry. Higher value mean better outcome.

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026